MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C by Thabet, Khaled et al.
ARTICLE
Received 17 Feb 2016 | Accepted 29 Jul 2016 | Published 15 Sep 2016
MBOAT7 rs641738 increases risk of liver
inflammation and transition to fibrosis
in chronic hepatitis C
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Cirrhosis likely shares common pathophysiological pathways despite arising from a variety of
liver diseases. A recent GWAS identified rs641738, a polymorphism in the MBOAT7 locus, as
being associated with the development of alcoholic cirrhosis. Here we explore the role of this
variant on liver inflammation and fibrosis in two cohorts of patients with chronic hepatitis C.
In 2,051 patients, rs641738 associated with severe hepatic inflammation and increased risk of
fibrosis, as well as fast fibrosis progression. At functional level, rs641738 associated with
MBOAT7 transcript and protein levels in liver and blood, and with serum inflammatory,
oxidative stress and macrophage activation markers. MBOAT7 was expressed in immune cell
subsets, implying a role in hepatic inflammation. We conclude that the MBOAT7 rs641738
polymorphism is a novel risk variant for liver inflammation in hepatitis C, and thereby for liver
fibrosis.
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A
bout 3% of the world population has been exposed to the
hepatitis C virus (HCV), a leading cause of liver-related
morbidity and mortality1. Not all patients with chronic
hepatitis C (CHC) will develop serious sequelae, with prognosis
and management largely depending on the extent and
progression of liver inflammation and fibrosis2. Complex and as
yet not fully understood interactions between the host, the virus
and the environmental factors modulate these outcomes, with
inflammation and fibrosis sharing common pathophysiological
pathways, despite differences in the cause of liver injury2.
A recent genome-wide association study followed by fine
mapping identified a novel single-nucleotide polymorphism
(SNP; rs641738) in the membrane bound O-acyltransferase
domain containing 7 gene (MBOAT7), also known as lysopho-
sphatidylinositol acyltransferase 1 (LPIAT1), to be associated with
alcoholic cirrhosis3. This association was recently extended to the
full histological spectrum of non-alcoholic fatty liver disease4.
MBOAT, a family of enzymes identified in 2000, comprises 11
genes that are involved in a variety of biological processes and are
considered as candidate therapeutic targets for several diseases
including obesity, viral infections, atherosclerosis and Alzheimer’s
disease5. MBOAT7 catalyses the transfer of an acyl-CoA to
lysophosphatidylinositol (lysoPI) and has a preference for
arachidonoyl-CoA. Thus, it might be one of the mechanisms by
which pro-inflammatory free arachidonic acid and eicosanoid
levels are regulated. Increased availability of arachidonic
acid leads to inflammatory signalling by prostaglandins and
leukotrienes, potent chemoattractant mediators of inflammation6.
We tested the hypothesis that MBOAT7 is a liver injury risk
locus in two large, well-characterized cohort of patients with
CHC, some of whom have been the subject of previous reports7,8.
Here we demonstrate that MBOAT7 rs641738 associates with
hepatic inflammation and the risk of liver fibrosis, as well as
fibrosis progression rate (FPR). MBOAT7 rs641738 regulated
MBOAT7 expression in opposite directions in liver and blood,
and associated with serum inflammatory, oxidative stress and
macrophage activation markers. MBOAT7 was expressed in
immune cell subsets, implying a role in hepatic inflammation.
These findings suggest that MBOAT7 is a novel liver injury risk
locus in CHC.
Results
Patient characteristics. Baseline characteristics of the discovery,
validation and overall cohorts of patients are shown in
Supplementary Table 1. The median age was 45 years with 65%
being male. About half (55%) had significant fibrosis (Metavir
score F2–4) and 45% had moderate/severe necroinflammation
(Metavir A2–A3). The discovery cohort included a higher
percentage of males who were younger at time of biopsy, with
higher liver enzymes. Both cohorts were similar with respect to
body mass index (BMI), platelet count, HCV-RNA levels and the
distribution of daily alcohol consumption over 50 g. The
prevalence of significant fibrosis was similar between the two
cohorts. The discovery cohort had more HCV genotype 3, and
the validation cohort more HCV genotype 1.
Genotype distribution, HWE calculations and genetic model.
The genotype distribution of MBOAT7 rs641738 was in Hardy–
Weinberg equilibrium (P¼ 0.1 for both CHC and healthy con-
trols cohorts). The minor allele frequency (MAF) was 0.45,
similar to that of the 270 Caucasian self-reported ‘healthy’ con-
trols (MAF¼ 0.45) and consistent with that previously reported
in the genome-wide association study on alcoholic cirrhosis3, and
in the healthy Caucasian population by the 1000 genome project
(Supplementary Table 2). There was no significant difference in
rs641738 allele frequency distribution according to patient
country of origin (Australia, UK, Germany, Italy and Spain;
P¼ 0.8 for trend by the Cochran–Armitage test).
Owing to a lack of current knowledge regarding the genetic
model of inheritance that might explain the effect of this variant,
we avoided choosing an a priori or arbitrary model as
recommended9.The best model is defined as the one with the
smallest Akaike information criterion (AIC) value. The dominant
model for the minor allele (T) best fitted the data and was the
most appropriate, as it had the lowest AIC value (Supplementary
Table 3). Hence, rs641738 comparisons were made using a
dominant model for the minor allele (T), unless otherwise
indicated.
Viral and clinical characteristics stratified by rs641738 genotype.
Apart from the fact that subjects with the rs641738 CC genotype
had significantly lower total leukocyte levels compared with
subjects with CT and TT, no other significant associations were
observed (Supplementary Table 4) with clinical characteristics,
liver enzymes, lipid profile or HCV-RNA. An association with the
leukocyte level was also significant when comparing the different
genotypes (P¼ 0.04, by analysis of variance after Bonferroni
correction for multiple comparisons).
To fully test the role of rs641738 in CHC, several primary and
exploratory analyses were undertaken. Primary analyses aimed to
test the association of rs641738 with liver injury (that is, hepatic
inflammation, fibrosis and fibrosis progression). The exploratory
analyses tested for the association of rs641738 with hepatic
steatosis and hepatocellular carcinoma (HCC).
rs641738 and hepatic inflammation and fibrosis in CHC.
Necroinflammatory activity was more pronounced in patients
carrying the minor allele (T) of MBOAT7 than in patients
carrying the major genotype, that is, a dominant model for the
minor allele. In the discovery cohort, the proportion of patients
with an activity score of Z2 was significantly higher in CT/TT
patients as compared with CC patients (51% versus 44%,
P¼ 0.03); this was replicated in the validation cohort (49% versus
40%, P¼ 0.02) and the overall cohort (50% versus 42%, P¼ 0.001;
Fig. 1a). By multiple logistic regression analysis adjusted for age,
gender, BMI, homeostatic model assessment of insulin resistance
(HOMA-IR), recruitment centre, alcohol consumption, viral load,
PNPLA3 rs738409, TM6SF2 rs58542926 and IFNL rs12979860
genotype, rs641738 CT/TT was independently associated with
higher necroinflammatory activity (odds ratio (OR): 1.44; 95%
confidence interval (CI): 1.14–1.72; P¼ 0.001; Supplementary
Table 5).
Using a recessive mode of inheritance, the proportion of
patients with any fibrosis (ZF1) was significantly higher in TT
compared with CC/CT patients (89% versus 82%, P¼ 0.04). The
same trend was observed in the validation cohort (94% versus
89%, P¼ 0.05) and was more significant in the overall cohort
(91% versus 86%, P¼ 0.006). This finding remained significant in
multiple logistic regression analyses adjusted for the same
variables listed above (OR: 1.69; 95% CI: 1.11–3.57; P¼ 0.02;
Supplementary Table 5). Notably, rs641738 did not influence the
likelihood of severe fibrosis (ZF3 versus F0–F2) (OR: 1.03; 95%
CI: 0.80–1.34; P¼ 0.7), significant fibrosis (ZF2 versus F0/F1) or
cirrhosis (F4 versus F0–F3), including when adopting other
genetic models. These data suggest that the effect of rs641738 is
restricted to the transition to fibrosis from an absence of fibrosis
(F0).
To further confirm this observation, we undertook analysis
in the sub-cohort with absent or mild fibrosis (n¼ 776)
and compared the effect of rs641738 on F0 versus F1 only.
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The analysis was restricted to the overall cohort to ensure
adequate power. Again, the TT genotype was associated with an
increased risk for the transition to fibrosis (OR: 1.78; 95% CI:
1.2–2.64; P¼ 0.004), a finding that remained significant in
multiple logistic regression analysis (OR: 1.69; 95% CI:
1.12–2.54; P¼ 0.01).
For additional confirmation, we undertook analysis in the
1,080 patients with CHC and a known duration of infection,
allowing us to assess the relationship with fibrosis progression.
The baseline characteristics of the cohort were similar among
subjects included and not included in the fibrosis progression
sub-analysis (Supplementary Table 6). The proportion of patients
with fast FPR was significantly higher in CT/TT patients as
compared with CC patients (52% versus 43%, P¼ 0.02; Fig. 1c).
The adjusted OR of the rs641738 (T) allele for having fast FPR
was 1.56; 95% CI: 1.03–2.36; P¼ 0.03. Because, fibrosis progres-
sion may not be constant over time and FPR assumes linearity, we
undertook further complementary analysis using multivariate
Cox proportional hazards adjusted for age, gender, BMI, PNPLA3
rs738409, TM6SF2 rs58542926 and IFNL rs12979860 genotype.
Again, the rs641738 (T) allele was associated with an increase in
the hazard of progression to fibrosis (ZF1; hazard ratio: 1.37;
95% CI: 1.05–2.16; P¼ 0.03; Fig. 1d).
MBOAT7 rs641738 and hepatic steatosis. Patients carrying
the MBOAT7 rs641738 (T) allele had a similar distribution
of steatosis grade as those with CC genotype (P¼ 0.8, Fig. 1b).
In univariate and multivariate analyses adjusted for the same
variables, rs641738 (T) allele was not associated with either the
severity of steatosis when subdividing the cohort according to
absent/mild steatosis (S0–S1) compared with moderate/severe
steatosis (S2–S3; OR: 0.99; 95% CI: 0.74–1.33; P¼ 0.9;
Supplementary Table 5) or with the presence of steatosis
(S0 versus S1–S3; OR: 0.92; 95% CI: 0.0.72–1.17; P¼ 0.5). No
difference was observed when stratifying the cohort according to
HCV genotype (genotype 3 (n¼ 343) versus non-3 (n¼ 1363))
based on the direct effect of genotype 3 on steatosis10, or by
adopting other genetic models, that is, additive or recessive
models.
Notably, there was no interaction observed between MBOAT7
rs641738 and either PNPLA3 rs738409 or TM6SF2 rs58542926
genotype regarding any of the histological features. Thus, the
effect of these three loci seems to be independent of each other,
suggesting that they regulate different pathways.
In sum, these data suggest that the MBOAT7 rs641738 (T)
allele has a more profound effect on hepatic inflammation and
the transition from absent fibrosis to early-stage liver fibrosis
(F1), with no effect on fibrosis progression to later stages (F2–4).
This effect was not due to an influence on hepatic steatosis and
independent of PNPLA3 rs738409, TM6SF2 rs58542926 and
IFNL rs12979860 genotype.
MBOAT7 rs641738 genotype and HCC. HCC is an
inflammation-induced cancer11; hence, we determined whether
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Figure 1 | Association of rs641738 genotype with liver injury. Association of rs641738 genotype with necroinflammation (a) and steatosis degree (b) by
discovery (n¼ 931), validation (n¼ 775) and overall cohorts (n¼ 1706). P values are univariate and provided for the dominant model of inheritance.
Association of rs641738 genotype with FPR in the sub-cohort with an estimated date of infection (n¼ 1,080) (c) with fast fibrosis progression.
(d) Multivariate Cox regression analysis of rs641738 genotypes on the cumulative probability of progression to any fibrosis (ZF1), adjusted for age,
gender, BMI, PNPLA3 rs738409, TM6SF2 rs58542926 and IFNL rs12979860 genotype. HR, hazard ratio.
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MBOAT7 rs641738 had an effect on HCV-related HCC. The
MBOAT7 rs641738 allele and genotype frequencies were
compared in 75 Caucasian patients with HCV-related HCC
to the entire CHC cohort described above (n¼ 1,706;
Supplementary Table 7). rs641738 MAF in the HCC cohort was
0.44, similar to the CHC cohort; no significant association was
observed with HCC (OR: 0.96; 95% CI: 0.58–1.57; P¼ 0.8) in
multivariate analysis after incorporating known risk factors,
including age, gender, BMI and Child-Pugh score. Again, these
findings imply that the role of rs641738 is limited to the early
stages of liver disease, but not to further progression or
occurrence of HCC.
rs641738 associates with MBOAT7 expression in liver and
blood. The association of rs641738 genotypes with the hepatic
expression of MBOAT7 mRNA and protein in patients with CHC
is unknown. In 94 liver biopsies of a sub-cohort of patients whose
baseline characteristics matched that of the overall cohort
(summarized in Supplementary Table 8), there was a significant
relationship between rs641738 genotype and MBOAT7 mRNA
expression (P¼ 0.03, Supplementary Fig. 1A); the same was
observed in analysis comparing subjects carrying the CC genotype
versus the CT/TT genotype (P¼ 0.02; Fig. 2a). The rs641738 (T)
allele remained independently associated with low hepatic MBOAT7
mRNA expression after adjustment for age, sex, BMI, alanine ami-
notransferase (ALT) and severity of liver disease (estimate
 0.095±0.02; P¼ 0.03). In a further analysis, MBOAT7 expres-
sion was significantly higher in subjects with none or mild hepatic
inflammation (A0–A1), compared with those with significant
hepatic inflammation (A2–A3; Fig. 2c). To determine if MBOAT7
expression is an adaptive response consequent to liver injury, we
compared MBOAT7 expression in CHC with low fibrosis (F0–F1)
(n¼ 45) with 28 controls without liver disease. MBOAT7 demon-
strated significantly higher expression in CHC (Po0.01; Fig. 2d).
This remained significant after stratification by MBOAT7 genotype
(Po0.05 for both alleles).
For further confirmation, we explored the level of MBOAT7
protein expression according to rs641738 genotype by immuno-
histochemistry using specific human anti-MBOAT7 antibody
(n¼ 9 subjects). Owing to the correlation between MBOAT7 and
hepatic inflammation and fibrosis, and to minimize confounding,
we restricted analysis to only subjects with no (F0) or early
fibrosis (F1). We observed that MBOAT7 immunoreactivity
was mainly in hepatocytes with predominant cytoplasmic
staining. We demonstrated significantly reduced MBOAT7
immunoreactivity in subjects carrying the (T) allele, compared
with those with CC genotype (Po0.03; Fig. 3).
We then explored whether MBOAT7 rs641738 regulates
transcript expression in blood as recent data indicates
that expression quantitative trait loci (eQTLs) may affect
gene expression in a tissue- and cell-dependent manner12.
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Figure 2 | Association of rs641738 genotype with MBOAT7 mRNA
expression. Association between MBOAT7 rs641738 genotype and hepatic
(n¼94) (a) and blood (n¼ 75) (b) MBOAT7 mRNA levels. Clinical and
anthropometric characteristics of these patients are shown in
Supplementary Table 8. The x axis shows the genotypes at rs641738 using
the dominant model of inheritance (CC¼ 35 and CT/TT¼ 59 in the liver
biopsy cohort, and CC¼ 23 and CT/TT¼ 52 in the blood cohort) and the y
axis shows the MBOAT7 expression level relative to GAPDH by quantitative
real-time PCR. (c) Hepatic MBOAT7 mRNA levels according to hepatic
inflammation. The x axis shows hepatic inflammation dichotomized as
absent/mild (METAVIR score A0–A1) (n¼ 53) or moderate/severe
(METAVIR score A2–A3) (n¼41), and the y axis shows hepatic MBOAT7
expression as fold change. The number of independent samples tested in
each group is shown in parentheses. Each group is shown as a box plot and
the median values are shown as thick dark horizontal lines. The box covers
the twenty-fifth to seventy-fifth percentiles. We tested the difference in the
median values among genotypes using the two-tailed Mann–Whitney tests.
We plotted the box plots using Graphpad prism 5. (d) Comparison of
hepatic MBOAT7 mRNA levels in hepatitis C patients with no or mild
fibrosis (F0–F1) (n¼45) and control (n¼ 28). The number of independent
samples tested in each group is shown in parentheses. Median and
interquartile range are shown and P value was calculated using the
two-tailed Mann–Whitney test.
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Figure 3 | Association of rs641738 genotype with MBOAT7 protein
expression. Association between hepatic MBOAT7 rs641738 genotype and
MBOAT7 protein expression assessed using immunohistochemistry (IHC).
(a) Scores for liver protein expression of MBOAT7 was evaluated using IHC
according to grouping of rs641738 genotype using the dominant model of
inheritance. The x axis shows the genotypes at rs641738 using the
dominant model of inheritance (CC¼ 3 and CT/TT¼ 6) and the y axis
shows the score of liver protein expression of MBOAT7. The number of
independent samples tested in each group is shown in parentheses.
(b) Representative liver expression pattern of MBOAT7 in patients carrying
the rs641738 CC or TT genotype, respectively. MBOAT7 immunoreactivity
was examined using light microscopy of liver sections. Original
magnification 400.
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Interestingly, rs641738 regulated MBOAT7 transcript expression
in blood (n¼ 75) in an opposite direction to that in liver, with
the (T) allele having the highest expression (Fig. 2 and
Supplementary Fig. 1B).
To identify the functional downstream effects of rs641738, we
conducted bioinformatics analysis. This demonstrated that the
rs641738 SNP is located in potentially functional regions containing
predicted transcription factor-binding motifs with protein-binding
sequences as demonstrated by ChIP-seq, located in the chromatin
structures and the histone modification regions. The RegulomeDB
score was 1b indicating that the SNP is likely to be functional
(Supplementary Table 9) (RegulomeDB score is scaled from 1a to 6
and the lower the score the more likely that the SNP affects binding
and is linked to the expression of a gene target; see Supplementary
Methods for more details). rs641738 was not associated with
microRNA-predicted binding affinity changes.
MBOAT7 is expressed by immune cells. HCV associated liver
pathology is characterized by an inflammatory infiltrate consisting
of different immune cell populations. The magnitude of this
inflammatory reaction determines histologic inflammatory activity
reflected in the METAVIR score, and is one of the major predictors
of progressive liver damage13. Apart from neutrophils14, MBOAT7
expression on other immune cells has not been investigated. We
therefore examined the expression of MBOAT7 in other immune
cell subsets (peripheral blood mononuclear cells (PBMCs), T and B
lymphocytes, monocytes, macrophages, natural killer cells, dendritic
cells and neutrophils); all cell types demonstrated good expression
of MBOAT7 (Fig. 4a). Further, MBOAT7 expression in whole
blood from 75 CHC patients was comparable to that in HCV-
infected liver biopsies (Fig. 4b).
rs641738 genotype and markers of inflammation. To char-
acterize the potential role of rs641738, we explored its association
with serum inflammatory and oxidative stress markers (tumour
necrosis factor-a (TNF-a), interleukin-6 (IL-6) and mal-
ondialdehyde (MDA)) in the sub-cohort of 95 subjects. Their
clinical and anthropometric characteristics are shown in
Supplementary Table 8. Consistent with the genetic data, TNF-a
levels, IL-6 levels and oxidative stress as measured by MDA were
higher for subjects carrying the rs641738 (T) allele compared with
those with the CC genotype (Po0.05, for all; Fig. 5).
We next examined the expression of other proinflammatory
cytokines to determine whether they differed by rs641738
genotype. To do this, we quantified the mRNA expression of
TNF-a, IL-1b, IL-6, CCL-19 and CCL-21 in blood from 75
patients. As shown in Supplementary Fig. 2, as well as having
higher TNF-a and IL-6 expression, subjects with the minor (T)
allele also had higher IL-1b compared with those with the major
CC genotype.
rs641738 and macrophage activation markers. Owing to the
high expression of MBOAT7 on immune cells, we also explored
the correlation of MBOAT7 rs641738 with serum sCD163,
a macrophage activation marker. Interestingly, subjects with
rs641738 (T) allele had significantly higher serum sCD163 com-
pared with those with the CC genotype (P¼ 0.04; Fig. 5).We
recently reported that sCD163 is associated with the severity of
300 bp
PB
M
C
M
BO
AT
7 
ex
pr
es
sio
n
CD
4 
Na
ive
B 
ce
lls
 m
em
or
y
N
eg
at
ive
 c
o
n
tro
l
PD
C
M
ac
ro
ph
ag
es
N
KCD
8
N
eu
tro
ph
ils
M
D
D
C
200 bp
100 bp
1.0
0.8
0.6
0.4
0.2
0.0
Liver
n = 94
Blood
n = 75
a
b
P = 0.08
Figure 4 | Expression of MBOAT7 in immune cells. (a) Expression of
MBOAT7 on circulating immune cells (PBMCs, T and B lymphocytes,
monocytes, macrophages, natural killer cells, dendritic cells (plasmacytoid
dendritic cells (PDCs) and monocyte-derived dendritic cells (MDDC)) and
neutrophils). (b) Comparison of the expression of MBOAT7 in blood
(n¼ 75) and liver (n¼94) in patients with CHC. The number of
independent samples tested in each group is shown in parentheses. Median
and interquartile range are shown; P value was calculated using the two-
tailed Mann–Whitney test.
20 P = 0.02 P = 0.02
P = 0.04P = 0.05
15
10
5
0
5
4
3
2
1
0
20
15
10
5
0
20
25
15
10
5
0
CC
n = 27
CT/TT
n = 68
CC
n = 27
CT/TT
n = 68
CC
n = 78
CT/TT
n = 332
CC
n = 27
CT/TT
n = 68
M
DA
 le
ve
ls
 (n
g m
l–1
)
TN
F-
α
 
le
ve
ls
 (p
g m
l–1
)
IL
-6
 le
ve
ls
 (p
g m
l–1
)
sC
D1
63
 (m
g l
–
1 )
a b
c d
Figure 5 | Association between rs641738 genotype and inflammatory,
oxidative stress and macrophage activation markers. rs641738 genotype
correlation with MDA, an oxidative stress marker (a), IL-6 (b) and TNF-a,
as inflammatory markers (c). Clinical and anthropometric characteristics of
these patients are shown in Supplementary Table 8 (n¼95). The x axis
shows the genotypes at rs641738 using the dominant model of inheritance
(CC¼ 27 and CT/TT¼ 68) and the y axis shows serum MDA as ngml 1
(a), IL-6 as pgml 1, TNF-a as pgml 1. (d) Association between MBOAT7
rs641738 genotype and the macrophage activation marker sCD163
(n¼ 510). The x axis shows the genotypes at rs641738 using the dominant
model of inheritance (CC¼ 178 and CT/TT¼ 332) and the y axis shows
sCD163 as mgml 1. The number of independent samples tested in each
group is shown in parentheses. Each group is shown as a box plot and the
median values are shown as thick dark horizontal lines. The box covers the
twenty-fifth to seventy-fifth percentiles. We tested the difference in the
median values among genotypes using the two-tailed Mann–Whitney test.
We plotted the box plots using Graphpad prism 5.
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liver disease15. To exclude the possibility that the association was
secondary to worsening liver disease, in a multivariable regression
model adjusting for age, the severity of liver disease and leukocyte
count, rs641738 remained independently associated with serum
sCD163 (P¼ 0.032).
Discussion
We evaluated the role of MBOAT7 rs641738, recently reported to
be a risk variant for alcoholic cirrhosis3, in two independent large
cohorts of patients with CHC. We observed that (1) MBOAT7
rs641738 is independently associated with inflammation and the
transition to early fibrosis; (2) hepatic MBOAT7 expression
correlates with inflammation; (3) rs641738 genotype has no
association with the severity of hepatic steatosis, HCC occurrence;
(4) rs641738 genotype associates with MBOAT7 transcript and
protein expression in liver and blood in opposite directions, and
with serum inflammatory, oxidative stress and macrophage
activation markers; and (5) MBOAT7 is well expressed by all
major immune cell subsets.
MBOAT7 (LPIAT1) is involved in membrane phospholipid
remodelling as it catalyses the transfer of an acyl-CoA to
lysophosphatidylinositol (lysoPI) with a high preference for
arachidonoyl-CoA. Thus, increased free arachidonic acid levels
in the context of reduced MBOAT7 expression may lead
to inflammatory signalling by arachidonic acid-derived prosta-
glandins and leukotrienes14. On the other hand, PI accumulation,
perhaps by reducing arachidonic acid levels, has been identified as
a potent anti-inflammatory molecule16.
In two cohorts of CHC patients comprising over 1,700 patients,
MBOAT7 rs641738 (T) allele associates with hepatic inflamma-
tion and the transition from normal liver to early fibrosis and
rapid fibrosis progression. Notably, the effect of this variant
disappeared with progression of disease, as it had no effect on the
late stages of fibrosis, cirrhosis or the occurrence of HCC. The
influence of rs641738 on inflammation appears to be more
profound than on fibrosis, as inflammation risk is increased in
carriers of even one copy of the risk rs641738 (T) allele. On the
other hand, for fibrosis, two copies of the risk allele are required
to have the effect, which was mainly for the transition from F0 to
F1 fibrosis. The predominant association with inflammation was
corroborated by coordinate changes in serum inflammatory,
oxidative stress and macrophage activation markers (TNF-a,
IL-6, MDA and sCD163). Collectively, these results imply that
MBOAT7 in the context of high expression plays an anti-
inflammatory role and thus may be a compensatory adaptation
during the early stages of HCV-induced inflammation. However,
in the context of ongoing liver injury, this homeostatic response
might possibly be no longer able to limit inflammation and
fibrosis. This hypothesis is supported by the observed negative
correlation between hepatic MBOAT7 expression and the extent
of liver inflammation and the elevated hepatic MBOAT7
expression in CHC patients with no or mild fibrosis, compared
with controls.
To provide contextual insights on the potential mechanisms by
which MBOAT7 might influence inflammation and fibrosis, we
considered several possibilities. MBOAT7 is involved in lipid
processing that has been linked to both the development of liver
inflammation and fibrosis17,18. However, we did not observe any
association of rs641738 with steatosis. Thus, the association
with inflammation and fibrosis is likely independent of lipid
accumulation and insulin resistance, and also of any other
lipid-related variants such as PNPLA3 and TM6SF2.
Activation of innate immune pathways in hepatocytes
following HCV infection leads to infiltration by inflammatory
immune cell populations18. The magnitude of this response is one
of the major predictors of progressive liver damage19. We
demonstrated strong MBOAT7 expression on all immune cell
subsets that infiltrate the liver during viral hepatitis. Further,
expression in these subsets was overall comparable to that in
HCV-infected liver biopsies, suggesting that it is part of a broad
adaptive response to injury.
Our expression analysis of MBOAT7 in peripheral blood
revealed an intriguing dissimilarity to liver, with the pro-
inflammatory risk allele (T) having higher expression in blood
but lower expression in liver. This result is consistent with eQTL
analysis of publicly available databases for rs641738 (ref. 20) and
recent data on non-alcoholic fatty liver disease4. These findings,
in line with several reports on other SNPs, suggest that many
genetic polymorphisms exert opposite effects on gene expression
in different cell types and tissue contexts21. This could be
explained by varying context-dependent regulatory mechanisms
for gene expression. However, an alternative explanation may be
that with initiation of liver injury, MBOAT7-expressing immune
cell recruitment to liver occurs in a genotype dependent manner
and is less in subjects with the risk T allele. Of relevance, those
with the T allele have significantly higher leukocytes compared
with those with the CC genotype. However, further study of
MBOAT7-expressing immune cell trafficking in response to
injury is required, before this hypothesis can be proven. Notably,
rs641738 is located in potentially functional regions that contain
predicted transcription factor-binding motifs.
In conclusion, we provide evidence for a role of MBOAT7
rs641738 as a novel risk variant for hepatic inflammation and
fibrosis in CHC. As MBOAT7 is expressed by all the principal
immune cell subsets, it could be considered as a potential target to
limit tissue inflammation in a variety of contexts.
Methods
Patient cohort. The study comprised 2,051 Caucasian consecutive subjects,
including 1,706 with CHC, 931 in the discovery cohort and 775 in the validation
cohort; 270 healthy controls and 75 with HCV-related HCC. Both the discovery
and validation cohorts are from the International Liver Disease Genetics
Consortium (ILDGC) database. Details of the cohort and inclusion criteria have
been reported7,8. Briefly, all consecutive subjects with HCV-RNA serum positivity
of Caucasian descent who had (a) a liver biopsy with scoring for fibrosis stage and
disease activity before anti-viral treatment, (b) genomic DNA and (c) provided
written consent for genetic analyses were included. Patients were excluded if they
had evidence of other liver diseases by standard tests including co-infection with
hepatitis B (surface antigen positivity) or human immunodeficiency virus, Wilson’s
disease, hereditary haemochromatosis, alpha1-antitrypsin deficiency or
autoimmune hepatitis.
Methods to estimate the duration of infection. Fibrosis progression was
examined in 1,080 CHC patients with a reliable estimated duration of infection7,22.
For subjects with a history of injecting drug use, the time of infection was estimated
using the reported ‘first year of injection’. For patients with a history of blood
transfusion, the onset of infection was assumed to be the year of transfusion. For
patients with a history of occupational exposure, the onset of infection was
assumed to be the first year of needle stick exposure. The duration of infection was
calculated by subtracting the estimated age at infection from age at biopsy. FPR was
determined by calculating the ratio between the fibrosis stage and the estimated
disease duration (in years).
The healthy Caucasian European control group was enrolled from Westmead
hospital, Sydney. They reported no history of chronic liver disease did not abuse
alcohol (o20 gm of alcohol daily) and did not have any of the features of the
metabolic syndrome according to the National Cholesterol Education Program
Adult Treatment Panel III criteria.
Ethics approvals were obtained from the Human Research Ethics Committees
of the Sydney West Area Health Service and the University of Sydney; Human
Research Ethics Committee; South Eastern Sydney Local Health District, NSW
Health; Ethic committee of St Vincent’s Hospital, Sydney; The Royal Perth
Hospital Human Research Ethics Committee, WA; Metro South Human Research
Ethics Committee, QLD; Human Research Ethics Committee, South Metropolitan
Health Service, Fremantle, WA; Sir Charles Gairdner Hospital Human Research
Ethics Committee, WA; Ethic Committee of Valme University Hospital, Seville;
Ethics Committees of Medical Research of the University of Leipzig, Berlin; Ethics
Committees of Medical Research the University of Berlin (Charite´), Berlin;
Northern & Yorkshire MREC, Nottingham; Ethical Committee of the Citta` della
Salute e della Scienza University Hospital, Torino; Ethical Committee IRCCS
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‘Casa Sollievo della Sofferenza’ Hospital San Giovanni Rotondo; Northumberland
Research Ethics Committee, Newcastle; Ethics Committee of the Medical Faculty,
Rheinische Friedrich-Wilhelms University Bonn, Bonn. All patients provided
written informed consent.
Clinical and laboratory assessment. The following data were collected at time of
liver biopsy for all patients: gender; age; ethnicity; recruitment centre, alcohol
intake (g per day), BMI and routine laboratory tests. Alcohol consumption was
assessed by two separate interviews with the patient and close family members.
BMI was calculated as weight divided by the square of the height (kgm 2).
The homeostasis model assessment (HOMA-IR) was calculated as (fasting serum
insulin (mUml 1) fasting serum glucose (mmol l ))/22.5.
Genotyping. Genotyping for MBOAT7 rs641738 was undertaken using the
TaqMan SNP genotyping allelic discrimination method (Applied Biosystems,
Foster City, CA, USA). All genotyping was blinded to clinical variables. PNPLA3
rs738409, TM6SF2 rs58542926 and IFNL rs12979860 genotyping were extracted
from our previous reports7,8.
Liver histopathology. Liver histopathology was scored according to METAVIR23.
Fibrosis was staged from F0 (no fibrosis) to F4 (cirrhosis). Necroinflammation (A)
was graded as A0 (absent), A1 (mild), A2 (moderate) or A3 (severe). The
inter-observer agreement between pathologists was studied previously and was
good (k¼ 77.5) for METAVIR staging using k statistics24. We further tested for the
inter-observer agreement between pathologists for fibrosis stage (F0–F1) and it was
excellent (k¼ 90). All pathology assessment was blinded to genotyping results.
Determination of inflammatory and oxidative stress markers. Serum TNF-a
and IL-6 were measured by sandwich enzyme-linked immunosorbent assay
(ELISA) and MDA was measured by reverse phase high performance liquid
chromatography in 95 subjects25,26.
Determination of macrophage activation markers. The plasma concentration of
sCD163 was determined in duplicate in samples that were collected at the time of
liver biopsy and stored at  80 C by an in-house sandwich ELISA using a BEP-
2000 ELISA-analyser (Dade Behring) in 510 patients27. Soluble CD163 is resistant
to repeated freezing and thawing27. Control samples and serum standards with
concentrations that ranged from 6.25 to 200 mg l 1 were included in each run. The
limit of detection (lowest standard) was 6.25 mg l 1. All sCD163 measurements
were performed at the Department of Clinical Biochemistry, Aarhus University
Hospital.
Separation of immune cell subsets and stimulation studies. EDTA tubes of
blood were collected from healthy participants, and separation of PBMCs on
Ficoll-Paque was performed. A number of cell subsets were isolated from the
PBMCs, including monocytes, plasmacytoid dendritic cells, natural killer cells,
B cells, T cells and neutrophils by EasySep isolation kits in accordance with the
manufacturer’s instructions. moDCs were generated from CD14-positive separated
cells by a 6-day culture in granulocyte–macrophage colony-stimulating factor
(GM-CSF; 67 ngml 1; eBioscience, San Diego, CA, USA) and recombinant human
IL-4 (17 ngml 1). Macrophages were generated from monocytes by stimulation
with GM-CSF or macrophage colony-stimulating factor (M-CSF) for 6 days in
culture. Purity was checked by flow cytometry after cell separation and was490%
in each case.
Real-time PCR. RNA was extracted from liver tissue of 94 well-characterized
patients with CHC who underwent liver biopsy at Westmead Hospital and had
stored liver tissue or serum, with no additional risk factors for liver steatosis or
fibrosis; that is, diabetes, obesity (BMI430 kgm 2), significant alcohol intake
(420 g per day), dyslipidaemia or use of cannabis and 28 sex- and age-matched
adult healthy controls with benign liver tumours for whom all causes of liver
disease were excluded, from PAXgene blood RNA tubes (n¼ 75 CHC) using the
RNeasy kit (Qiagen) according to the manufacturer’s instructions. RNA quality
and concentration was assessed using the Agilent 2100 Bioanalyser (Agilent,
Waldbronn, Germany). cDNA was prepared using qscript (Quanta Biosciences,
Gaithersburg, MD, USA) in a Mastercycler gradient 5331 (Eppendorf AG,
Hamburg, Germany). Gene expression for MBOAT7, TNF-a, IL-1b, IL-6, CCL-19
and CCL-21 was measured by qPCR. GAPDH was used as the house-keeping
gene. Expression was measured using CT values, normalized to that of
GAPDH (DCT¼CT (GAPDH) CT (target) and then expressed as 2DCT.
All amplifications were done in duplicate. qPCR primer sequences are listed in
Supplementary Table 10.
Immunohistochemical staining. Immunostaining for MBOAT7 was performed
on liver biopsies of CHC patients. Formalin-fixed, paraffin-embedded 4 mm
sections were stained using a Ventana Benchmark Immunostainer (Ventana
Medical Systems, Inc, Arizona, USA). Slides were incubated with a dilution of
1:10 of rabbit polyclonal antibody (Ab) specific for Human MBOAT7 (SIGMA
ALDRICH). Negative controls where the primary antibody was excluded
confirmed the specificity of immunostaining. Detection was performed using
Ventana’s Ultra View DAB kit (Roche/Ventana 05269806001). The pathologist
(D.M.) evaluated the MBOAT7 immunostaining semi-quantitatively in a blinded
fashion regarding any of the histological and clinical characteristics of the patients.
The extent of staining was scored according to its amount and intensity using a
4-point scoring system as follows: 0¼ no staining; 1¼ positive staining ino33% of
cells; 2¼ 33–66% of positive cells; and 3¼ positive staining in more than 66%
of cells.
Bioinformatic analysis of the rs641738 SNP and functional prediction. To
identify the potential functional effects of rs641738 on MBOAT7 expression in
blood, data sets that have evaluated constitutive RNA expression by mapping
eQTLs in peripheral blood samples from 8,086 individuals was interrogated28.
With the use of the ENCODE data (http://www.genome.gov/10005107)29, we
conducted a bioinformatics analysis to predict the function of MBOAT7rs641738.
The ENCODE data provide a multitude of experimental data suitable to annotate
regulatory variants outside of protein-coding regions, and this was achieved by the
Regulome DB (http://www.regulomedb.org)30, a fairly comprehensive variant
annotation tool that makes use of functional sources. We also predicted whether
the rs641738 is located in the microRNA-binding sites using an online-tool
mirSNP (http://202.38.126.151/hmdd/mirsnp/search/)31.
Statistical analysis. Statistical analyses were performed using the statistical
software package SPSS for Windows, version 21(SPSS, Chicago, IL). Results
are expressed as mean±s.d., median and interquartile range or number
(percentage) of patients. The Student’s t-test or non-parametric, that is,
Wilcoxon–Mann–Whitney U-test or Kruskal–Wallis tests were used to compare
quantitative data, as appropriate. w2-test and Fisher-exact tests were used for
comparison of frequency data and to evaluate the relationships between groups and
the Cochran–Armitage test for trend. All tests were two-tailed and P valueso0.05
were considered significant.
Multivariable regression modelling with backward elimination was undertaken
to test independent associations of the MBOAT7 rs641738 variant with the
following outcome variables: (a) steatosis; (b) inflammation; and (c) fibrosis using
ordinal regression models for ordinal traits (severity of steatosis,
necroinflammatory activity and stage of fibrosis), and logistic regression models to
examine binary traits; steatosis dichotomized as absent (S0) versus steatosis of any
degree (ZS1), and in another analysis, as absent/mild (S0–S1) or moderate/severe
(S2–S3); necroinflammation was dichotomized as absent/mild (METAVIR score
A0–A1) or moderate/severe (METAVIR score A2–A3), and fibrosis as no fibrosis
(F0) and fibrosis (F1–F4), absent/mild (METAVIR score F0–F1) or significant
(METAVIR score F2–F4), none/moderate fibrosis (F0–F2) or severe fibrosis
(F3–F4) and no cirrhosis (F0–F3) and cirrhosis (F4). Final models were assessed
using the Hosmer–Lemeshow goodness of fit and Pearson goodness-of-fit tests.
Analyses were adjusted for biologically relevant covariates and potential
confounders associated with the risk of liver disease progression (age, gender, BMI,
HOMA-IR, recruitment centre, alcohol consumption, viral load, PNPLA3
rs738409, TM6SF2 rs58542926 and IFNL rs12979860 genotype). HCV-RNA levels
were log-transformed before entry into the model. Results are expressed as beta
b±s.e. or OR and 95% CI. The OR estimates the relative change in the rate of the
outcome (for example, significant fibrosis) per unit increase in the explanatory
variable. Interactions among genes were tested by adding the corresponding gene
X gene (GXG) interaction terms to the multivariable-adjusted regression models.
FPR was determined by calculating the ratio between the fibrosis stage and the
estimated disease duration (in years). For FPR analysis, patients were stratified into
two groups of stage-constant FPR according to the median rate (0.076 fibrosis units
per year), which was used as a cutoff. We then used Cox regression analysis to
model the time taken for any fibrosis (ZF1) to develop. For this, after checking the
normality of the quantified variables, appropriate logarithmic transformations were
made. We considered estimated age at infection as the starting point and the liver
biopsy showing any fibrosis (failure time) or the liver biopsy showing an absence
of any fibrosis in the absence of treatment (censored time) as the end point.
A Cox proportional-hazards regression model was fitted, and the covariates were
considered significant if Po0.05.Multivariate adjusted analyses were used, with
age, gender, BMI, PNPLA3 rs738409, TM6SF2 rs58542926 and IFNL rs12979860
genotype as covariates.
Multivariable regression modelling with backward elimination was undertaken
to test independent associations with hepatic MBOAT7 mRNA expression.
Analysis was adjusted for age, sex, BMI, ALT and severity of liver disease. Final
models were assessed using the Hosmer–Lemeshow goodness of fit and Pearson
goodness-of-fit tests. Similarly, another model adjusting for severity of liver disease
and leukocyte count was applied to assess the independent association of rs641738
with serum sCD163 levels.
We examined five potential genetic models that might explain the effect of
rs641738 on liver histology outcome: co-dominant; dominant; recessive; over
dominant; and additive. We investigated which model was the most appropriate
by calculating the AIC values32. The lowest AIC is indicative of the best fit.
The strength of the association between rs641738 and moderate/severe
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inflammation under each model was expressed by ORs and their corresponding
95% CIs. Using the CaTS power calculator for genetic association studies33, and
assuming rs641738 MAF of 0.45, our cohort had 98% power for the dominant
genetic model for the recessive allele and 96% power for the recessive one for liver
histology outcomes (steatosis, inflammation and fibrosis).
Data availability. The data that support the findings of this study are available
from the corresponding author on a reasonable request.
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